Tissue-engineering company Organovo Holdings (NASDAQ: ONVO) climbed as much as 14% just before noon EDT today, after announcing that its ExVive Human Kidney Tissue was generating strong customer response following its recent launch in September.
The ExVive product is designed to allow researchers to more effectively assess drug toxicity. The 3D structure of Organovo's tissue samples is a more accurate representation of the complexity of the human body than 2D modeling. While there's a long way to go in recreating that complexity, even the early days of tissue engineering mark significant improvements in several important quantitative metrics. That's because most drugs end up failing clinical trials -- even late-stage clinical trials -- due to toxicity. If the pharmaceutical industry could learn of drug-tissue relationships earlier in the development process, then it could slash billions from drug development expenses and devote more resources to more promising therapeutic candidates.
In other words, on paper the potential value promised to be delivered by tissue-engineering products is tremendous. There's just been a problem with the delivery part. Will this time be different?
Perhaps. Since launching in September, the ExVive human kidney tissue launch is receiving a "strong customer response," according to Organovo. Investors are left to determine if that is synonymous with "demand" or whether the response will have a meaningful impact on the top line. That aside, investors applauded the update, especially the disclosure that Organovo has commercial orders from two top-25 pharmaceutical companies.
On one hand, any sign of market traction is a big deal for Organovo, which has struggled to achieve meaningful growth in the last several years. The innovative products in its portfolio have failed to find their footing or provide more than a trickle of quarterly revenue. The technology may have arrived too early to be appreciated.
On the other hand, this "newsworthy development" probably didn't deserve a press release. Investors have been here before with Organovo: Products are launched and minute details on market development are released, but they never seem to translate to growth for the top or bottom line. While the company managed to grow revenue 187% in the second quarter of 2016 compared to the year-ago period, it's still only generating a paltry $890,000 in quarterly sales. That's not going to reverse the tide of quarterly operating losses any time soon.
Investors will need to continue to have patience with Organovo. The potential is certainly there, but a lack of execution should not go unnoticed.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.